Checkpoint inhibition in meningiomas. (June 2016)

• Record Type: Journal Article
• Authors: Bi, Wenya Linda; Wu, Winona W; Santagata, Sandro; Reardon, David A; Dunn, Ian F
• Is Part Of: Immunotherapy. Volume 8:Number 6(2016:Jun.)
• Page Start: 721
• Page End: 731
• Publication Date: 2016-06
• Subjects: checkpoint inhibition -- immunotherapy -- meningioma -- PD-1 -- PD-L1 -- targeted pharmacotherapy; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2016-0017
• Languages: English
• ISSNs: 1750-743X

Abstract

Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evidence support a role for immune-based therapeutic strategies in the management of meningiomas, especially high-grade subtypes. Meningiomas frequently originate juxtaposed to venous sinuses, where an anatomic conduit for lymphatic drainage resides. Multiple populations of immune cells have been observed in meningiomas. PD-1/PD-L1 mediated immunosuppression has been implicated in high-grade meningiomas, with association between PD-L1 expression with negative prognostic outcome. These data point to the promise of future combinatorial therapeutic strategies in meningioma.